High-Risk Medicines Classification of cancer drugs is now under way

The National High-Risk Medicines Classification is an information product on medication safety held by the Finnish Medicines Agency, Fimea. It was published in spring 2023. The Classification helps health care professionals to identify the key high-risk medicines and the risks associated with them, and to ensure that these medicines are used safely. The Classification includes descriptions of the serious consequences of medicines and risk points in the medication process.  

Fimea, in collaboration with key stakeholders, has started to develop the High-Risk Medicines Classification of cancer drugs. The output will be similar to the previously published National High-Risk Medicines Classification. 

The aim of the Classification of cancer drugs is to identify the key cancer drugs in use and to describe their key risks to make their use safer and to prevent or identify potential adverse effects. A group of experts is drafting the classification, and when the data content is being finalised, there will be an opportunity for public comments, the date for which will be announced later. 

Read more:

National High-Risk Medicines Classification

National High-Risk Medicines Classification Preparation of the data content (Julkari, in Finnish, abstract in English)